Evidence map›Paper›PMID 33881668›Full record

ArticleInternational ophthalmology2021

Ultrasonic circular cyclocoagulation prospective safety and effectiveness study.

Tiago Morais Sarmento, Ricardo Figueiredo, João Garrido, Inês Passos, Ana Luísa Rebelo, Augusto Candeias

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tiago Morais SarmentoOphthalmology Department of Hospital Espírito Santo de Évora, Serviço de Oftalmologia Do Hospital Do Espírito Santo de Évora, Largo Senhor da Pobreza, 7000-811, Évora, Portugal. tiagomsarmento@edu.ulisboa.pt.ORCID http://orcid.org/0000-0003-2648-3496
Ricardo FigueiredoOphthalmology Department of Hospital Espírito Santo de Évora, Serviço de Oftalmologia Do Hospital Do Espírito Santo de Évora, Largo Senhor da Pobreza, 7000-811, Évora, Portugal.
João GarridoOphthalmology Department of Hospital Espírito Santo de Évora, Serviço de Oftalmologia Do Hospital Do Espírito Santo de Évora, Largo Senhor da Pobreza, 7000-811, Évora, Portugal.
Inês PassosOphthalmology Department of Centro Hospitalar, Universitário Lisboa Central, Lisbon, Portugal.
Ana Luísa RebeloOphthalmology Department of Hospital Espírito Santo de Évora, Serviço de Oftalmologia Do Hospital Do Espírito Santo de Évora, Largo Senhor da Pobreza, 7000-811, Évora, Portugal.
Augusto CandeiasOphthalmology Department of Hospital Espírito Santo de Évora, Serviço de Oftalmologia Do Hospital Do Espírito Santo de Évora, Largo Senhor da Pobreza, 7000-811, Évora, Portugal.
Hospital do Espírito Santo · PTUnidade Local de Saúde de São José · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of ultrasound cycloplasty procedures (UCP) in patients with uncontrolled glaucoma.

methodsProspective longitudinal study with UCP was performed by EyeOP1© probe with 8 s duration on 6 or 8 sectors, according to baseline intraocular pressure (IOP). Complete ophthalmic examination was performed pre- and post-operatively at 1st day, 1st week, 1st, 3rd, 6th, 9th and 12th months. UCP was repeated beyond 3rd month if IOP was > 21 mmHg, under maximum therapy, without major complications. Primary outcomes were complete (IOP reduction ≥ 20% or reduction in number of antiglaucomatous drugs and IOP ≥ 5 mmHg without occurrence of major complications) and qualified (IOP reduction ≥ 20% or reduction in number of antiglaucomatous drugs and IOP ≥ 5 mmHg) surgical success rates at 12 months. Secondary outcomes were mean IOP reduction, mean number of drugs reduction, rates of failure, number of repeated procedures, mean time to failure and occurrence of complications.

resultsFourteen eyes of 13 patients (11 male) with advanced glaucoma (Hoddap classification) were included. Six were surgically naïve. Mean age was 68.29 ± 10.66 years. Four eyes were treated in 8 sectors (28.5%). Patients were followed for 12 months after first UCP procedure. Overall surgical success was achieved in 92.9% at 6 months and in 100% of cases at 12 months. Mean IOP significantly reduced from 28.50 ± 7.61 mmHg to 13.79 ± 6.97 at 1 month, 17.36 ± 8.58 at 3 months, 17.79 ± 6.29 at 6 months, 16.3 ± 4.6 at 9 months and to 15.23 ± 5.09 at 12 months (p < 0.01). Mean number of drugs reduced from 3.71 ± 0.61 to 2.43 ± 1.51 at 3 months, 2.86 ± 1.1 at 6 months, 2.64 ± 0.93 at 9 months and to 2.92 ± 0.86 at 12 months (p < 0.05). Major reversible complications included choroidal detachment in 2 (14.29%) and corneal edema in 1 eye (7.14%), without permanent visual acuity reduction. Minor reversible complications included anterior chamber reaction (92.25%), conjunctival hyperemia (71.43%) and superficial keratitis (57.4%). Four eyes (28.57%) had indication for repeating UCP, with mean period to failure of 8.1 ± 3.95 months.

conclusionUCP procedures are effective in reducing IOP in severe glaucoma. Its application and repetition seem to be a medium-long term acceptable alternative to cyclodestructive surgery. However, long-term efficacy and safety require yet further investigation.

Indexed as

Ciliary BodyUltrasonicsAgedFollow-Up StudiesHumansIntraocular PressureLongitudinal StudiesMaleMiddle AgedProspective StudiesTreatment OutcomeCiliary BodyCyclocoagulationGlaucomaHigh-intensity focused ultrasoundNoninvasive glaucoma procedureUltrasonic cyclodestruction

Identifiers

PMID33881668
OpenAlexW3153541289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.